Background: Translational surgical research can range from investigating clinically oriented basic pathophysiological research via the correlation of molecular findings with a patient's clinical outcome to conducting treatment response studies. Herein, the specialist's opinion as a ‘surgeon scientist' plays a pivotal role, e.g. in planning experimental setups focusing on the clinically most relevant needs. Summary and Key Messages: This review provides a survey of genomic and proteomic technologies and gives an up-to-date overview of those studies applying these technologies exemplarily in colorectal cancer-based biomarker research. Although current results are promising, future validation studies within multicenter networks are required to promote the translation of ‘omics' from bench to bedside. In this endeavor, departments of surgery and institutes of experimental surgery together should play a fundamental role. The program for ‘clinician scientists' recently launched by the German Research Society (DFG) could be one tool to promote interdisciplinary networks and surgeons' impact on translational research.

Keywords:
Genomics, Proteomics, Translational research, Colorectal cancer, Surgery
1.
Reimers MS, Engels CC, Kuppen PJ, van de Velde CJ, Liefers GJ: How does genome sequencing impact surgery? Nat Rev Clin Oncol 2014;11:610-618.
2.
Roblick UJ, Auer G: Proteomics and clinical surgery. Br J Surg 2005;92:1464-1465.
3.
Habermann JK, Bader FG, Franke C, Zimmermann K, Gemoll T, Fritzsche B, Ried T, Auer G, Bruch HP, Roblick UJ: From the genome to the proteome - biomarkers in colorectal cancer. Langenbecks Arch Surg 2008;393:93-104.
4.
Hewitt RE: Biobanking: the foundation of personalized medicine. Curr Opin Oncol 2011;23:112-119.
5.
Gaffney EF, Madden D, Thomas GA: The human side of cancer biobanking. Methods Mol Biol 2012;823:59-77.
6.
Betsou F, Lehmann S, Ashton G, Barnes M, Benson EE, Coppola D, DeSouza Y, Eliason J, Glazer B, Guadagni F, Harding K, Horsfall DJ, Kleeberger C, Nanni U, Prasad A, Shea K, et al: Standard preanalytical coding for biospecimens: defining the sample PREanalytical code. Cancer Epidemiol Biomarkers Prev 2010;19:1004-1011.
7.
Végvári A, Welinder C, Lindberg H, Fehniger TE, Marko-Varga G: Biobank resources for future patient care: developments, principles and concepts. J Clin Bioinforma 2011;1:24.
8.
Riegman PH, Morente MM, Betsou F, de Blasio P, Geary P: Biobanking for better healthcare. Mol Oncol 2008;2:213-222.
9.
Schmitt M, Mengele K, Schueren E, Sweep FC, Foekens JA, Brunner N, Laabs J, Malik A, Harbeck N: European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers. Eur J Cancer 2007;43:835-844.
10.
Oberländer M, Linnebacher M, König A, Bogoevska V, Brodersen C, Kaatz R, Krohn M, Hackmann M, Ingenerf J, Christoph J, Mate S, Prokosch HU, Yekebas EF, Thorns C, Büning J, Prall F, et al: The ‘North German Tumor Bank of Colorectal Cancer': status report after the first 2 years of support by the German Cancer Aid Foundation. Langenbecks Arch Surg 2013;398:251-258.
11.
Huber-Lang M, Neugebauer E: The dual role of academic surgeons as clinicians and researchers - an attempt to square the circle? Patient Saf Surg 2011;5:16.
12.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917.
13.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
14.
Connell W: PRO: Endoscopic surveillance minimizes the risk of cancer. Am J Gastroenterol 2004;99:1631-1633.
15.
de Wijkerslooth TR, Bossuyt PM, Dekker E: Strategies in screening for colon carcinoma. Neth J Med 2011;69:112-119.
16.
Caspersson T, Zech L, Johansson C, Modest EJ: Identification of human chromosomes by DNA-binding fluorescent agents. Chromosoma 1970;30:215-227.
17.
Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D: Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992;258:818-821.
18.
Schröck E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, Ning Y, Ledbetter DH, Bar-Am I, Soenksen D, Garini Y, Ried T: Multicolor spectral karyotyping of human chromosomes. Science 1996;273:494-497.
19.
Speicher MR, Gwyn Ballard S, Ward DC: Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nat Genet 1996;12:368-375.
20.
Dumanoir S, Speicher MR, Joos S, Schröck E, Popp S, Döhner H, Kovacs G, Robert-Nicoud M, Lichter P, Cremer T: Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization. Hum Genet 1993;90:590-610.
21.
Ried T, Liyanage M, du Manoir S, Heselmeyer K, Auer G, Macville M, Schröck E: Tumor cytogenetics revisited: comparative genomic hybridization and spectral karyotyping. J Mol Med (Berl) 1997;75:801-814.
22.
Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, Chen C, Zhai Y, Dairkee SH, Ljung BM, Gray JW, Albertson DG: High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998;20:207-211.
23.
Ahn JW, Coldwell M, Bint S, Mackie Ogilvie C: Array comparative genomic hybridization (array CGH) for detection of genomic copy number variants. J Vis Exp 2015;96:e51718.
24.
Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner A, Döhner H, Cremer T, Lichter P: Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 1997;20:399-407.
25.
Oostlander AE, Meijer GA, Ylstra B: Microarray-based comparative genomic hybridization and its applications in human genetics. Clin Genet 2004;66:488-495.
26.
Bejjani BA, Shaffer LG: Application of array-based comparative genomic hybridization to clinical diagnostics. J Mol Diagn 2006;8:528-533.
27.
Ren H, Francis W, Boys A, Chueh AC, Wong N, La P, Wong LH, Ryan J, Slater HR, Choo KH: BAC-based PCR fragment microarray: high-resolution detection of chromosomal deletion and duplication breakpoints. Hum Mutat 2005;25:476-482.
28.
Urban AE, Korbel JO, Selzer R, Richmond T, Hacker A, Popescu GV, Cubells JF, Green R, Emanuel BS, Gerstein MB, Weissman SM, Snyder M: High-resolution mapping of DNA copy alterations in human chromosome 22 using high-density tiling oligonucleotide arrays. Proc Natl Acad Sci USA 2006;103:4534-4539.
29.
Langer-Safer PR, Levine M, Ward DC: Immunological method for mapping genes on Drosophila polytene chromosomes. Proc Natl Acad Sci USA 1982;79:4381-4385.
30.
Cremer T, Landegent J, Brückner A, Scholl HP, Schardin M, Hager HD, Devilee P, Pearson P, van der Ploeg M: Detection of chromosome aberrations in the human interphase nucleus by visualization of specific target DNAs with radioactive and non-radioactive in situ hybridization techniques: diagnosis of trisomy 18 with probe L1.84. Hum Genet 1986;74:346-352.
31.
Le Beau MM: Detecting genetic changes in human tumor cells: have scientists ‘gone fishing?'. Blood 1993;81:1979-1983.
32.
Mardis ER: Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 2008;9:387-402.
33.
Ross JS, Cronin M: Whole cancer genome sequencing by next-generation methods. Am J Clin Pathol 2011;136:527-539.
34.
Metzker ML: Sequencing technologies - the next generation. Nat Rev Genet 2010;11:31-46.
35.
Huber J, Böni J, Trkola A: Molekulare virologische Diagnostik im Wandel: Next Generation Sequencing auf dem Weg in die diagnostische Routine? Pipette 2013;5:15-17.
36.
Wilkins MR, Sanchez JC, Gooley AA, Appel RD, Humphery-Smith I, Hochstrasser DF, Williams KL: Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev 1996;13:19-50.
37.
Alvarez-Chaver P, Otero-Estévez O, Páez de la Cadena M, Rodríguez-Berrocal FJ, Martínez-Zorzano VS: Proteomics for discovery of candidate colorectal cancer biomarkers. World J Gastroenterol 2014;20:3804-3824.
38.
Seibert V, Ebert MP, Buschmann T: Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery. Brief Funct Genomic Proteomic 2005;4:16-26.
39.
Gemoll T, Roblick UJ, Auer G, Jörnvall H, Habermann JK: SELDI-TOF serum proteomics and colorectal cancer: a current overview. Arch Physiol Biochem 2010;116:188-196.
40.
Wilkins MR, Pasquali C, Appel RD, Ou K, Golaz O, Sanchez JC, Yan JX, Gooley AA, Hughes G, Humphery-Smith I, Williams KL, Hochstrasser DF: From proteins to proteomes: large scale protein identification by two-dimensional electrophoresis and amino acid analysis. Biotechnology (NY) 1996;14:61-65.
41.
Pandey A, Mann M: Proteomics to study genes and genomes. Nature 2000;405:837-846.
42.
Molloy MP, Witzmann FA: Proteomics: technologies and applications. Brief Funct Genomic Proteomic 2002;1:23-39.
43.
Gemoll T, Roblick UJ, Habermann JK: MALDI mass spectrometry imaging in oncology (review). Mol Med Rep 2011;4:1045-1051.
44.
Melle C, Ernst G, Schimmel B, Bleul A, Thieme H, Kaufmann R, Mothes H, Settmacher U, Claussen U, Halbhuber KJ, Von Eggeling F: Discovery and identification of α-defensins as low abundant, tumor-derived serum markers in colorectal cancer. Gastroenterology 2005;129:66-73.
45.
Meding S, Balluff B, Elsner M, Schöne C, Rauser S, Nitsche U, Maak M, Schäfer A, Hauck SM, Ueffing M, Langer R, Höfler H, Friess H, Rosenberg R, Walch A: Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer. J Pathol 2012;228:459-470.
46.
Molloy RM, McConnell RI, Lamont JV, FitzGerald SP: Automation of biochip array technology for quality results. Clin Chem Lab Med 2005;43:1303-1313.
47.
FitzGerald SP, McConnell RI, Huxley A: Simultaneous analysis of circulating human cytokines using a high-sensitivity cytokine biochip array. J Proteome Res 2008;7:450-455.
48.
Gordon DJ, Resio B, Pellman D: Causes and consequences of aneuploidy in cancer. Nat Rev Genet 2012;13:189-203.
49.
Burrell RA, McGranahan N, Bartek J, Swanton C: The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013;501:338-345.
50.
Araujo SEA, Bernardo WM, Habr-Gama A, Kiss DR, Cecconello I: DNA ploidy status and prognosis in colorectal cancer: a meta-analysis of published data. Dis Colon Rectum 2007;50:1800-1810.
51.
Ried T, Knutzen R, Steinbeck R, Blegen H, Schröck E, Heselmeyer K, du Manoir S, Auer G: Comparative genomic hybridization reveals a specific pattern of chromosomal gains and losses during the genesis of colorectal tumors. Genes Chromosomes Cancer 1996;15:234-245.
52.
Bomme L, Bardi G, Pandis N, Fenger C, Kronborg O, Heim S: Clonal karyotypic abnormalities in colorectal adenomas - clues to the early genetic events in the adenoma-carcinoma sequence. Genes Chromosomes Cancer 1994;10:190-196.
53.
Ghadimi BM, Sackett DL, Difilippantonio MJ, Schröck E, Neumann T, Jauho A, Auer G, Ried T: Centrosome amplification and instability occurs exclusively in aneuploid, but not in diploid colorectal cancer cell lines, and correlates with numerical chromosomal aberrations. Genes Chromosomes Cancer 2000;27:183-190.
54.
Habermann JK, Paulsen U, Roblick UJ, Upender MB, McShane LM, Korn EL, Wangsa D, Krüger S, Duchrow M, Bruch HP, Auer G, Ried T: Stage-specific alterations of the genome, transcriptome, and proteome during colorectal carcinogenesis. Genes Chromosomes Cancer 2007;46:10-26.
55.
Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med 2004;10:789-799.
56.
Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
57.
Habermann JK, Brucker CA, Freitag-Wolf S, Heselmeyer-Haddad K, Krüger S, Barenboim L, Downing T, Bruch HP, Auer G, Roblick UJ, Ried T: Genomic instability and oncogene amplifications in colorectal adenomas predict recurrence and synchronous carcinoma. Mod Pathol 2011;24:542-555.
58.
Upender MB, Habermann JK, McShane LM, Korn EL, Barrett JC, Difilippantonio MJ, Ried T: Chromosome transfer induced aneuploidy results in complex dysregulation of the cellular transcriptome in immortalized and cancer cells. Cancer Res 2004;64:6941-6949.
59.
Gerling M, Meyer KF, Fuchs K, Igl BW, Fritzsche B, Ziegler A, Bader F, Kujath P, Schimmelpenning H, Bruch HP, Roblick UJ, Habermann JK: High frequency of aneuploidy defines ulcerative colitis-associated carcinomas: a prognostic comparison to sporadic colorectal carcinomas. Ann Surg 2010;252:74-83.
60.
Habermann J, Lenander C, Roblick UJ, Krüger S, Ludwig D, Alaiya A, Freitag S, Dümbgen L, Bruch HP, Stange E, Salo S, Tryggvason K, Auer G, Schimmelpenning H: Ulcerative colitis and colorectal carcinoma: DNA-profile, laminin-5 γ2 chain and cyclin A expression as early markers for risk assessment. Scand J Gastroenterol 2001;36:751-758.
61.
Fozard JB, Quirke P, Dixon MF, Giles GR, Bird CC: DNA aneuploidy in ulcerative colitis. Gut 1986;27:1414-1418.
62.
Befrits R, Hammarberg C, Rubio C, Jaramillo E, Tribukait B: DNA aneuploidy and histologic dysplasia in long-standing ulcerative colitis. A 10-year follow-up study. Dis Colon Rectum 1994;37:313-319; discussion 319-320.
63.
Gerling M, Nousiainen K, Hautaniemi S, Krüger S, Fritzsche B, Homann N, Bruch HP, Auer G, Roblick UJ, Ried T, Habermann JK: Aneuploidy-associated gene expression signatures characterize malignant transformation in ulcerative colitis. Inflamm Bowel Dis 2013;19:691-703.
64.
Meyerson M, Gabriel S, Getz G: Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet 2010;11:685-696.
65.
Tran B, Dancey JE, Kamel-Reid S, McPherson JD, Bedard PL, Brown AM, Zhang T, Shaw P, Onetto N, Stein L, Hudson TJ, Neel BG, Siu LL: Cancer genomics: technology, discovery, and translation. J Clin Oncol 2012;30:647-660.
66.
Han SW, Kim HP, Shin JY, Jeong EG, Lee WC, Lee KH, Won JK, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Seo JS, et al: Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. PLoS One 2013;8:e64271.
67.
Xie T, Cho YB, Wang K, Huang D, Hong HK, Choi YL, Ko YH, Nam DH, Jin J, Yang H, Fernandez J, Deng S, Rejto PA, Lee WY, Mao M: Patterns of somatic alterations between matched primary and metastatic colorectal tumors characterized by whole-genome sequencing. Genomics 2014;104:234-241.
68.
Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-892.
69.
O'Connell MJ, Lavery I, Yothers G, Paik S, Clark-Langone KM, Lopatin M, Watson D, Baehner FL, Shak S, Baker J, Cowens JW, Wolmark N: Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010;28:3937-3944.
70.
Gray RG, Quirke P, Handley K, Lopatin M, Magill L, Baehner FL, Beaumont C, Clark-Langone KM, Yoshizawa CN, Lee M, Watson D, Shak S, Kerr DJ: Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 2011;29:4611-4619.
71.
Tyers M, Mann M: From genomics to proteomics. Nature 2003;422:193-197.
72.
Listgarten J, Emili A: Statistical and computational methods for comparative proteomic profiling using liquid chromatography-tandem mass spectrometry. Mol Cell Proteomics 2005;4:419-434.
73.
Xie LQ, Zhao C, Cai SJ, Xu Y, Huang LY, Bian JS, Shen CP, Lu HJ, Yang PY: Novel proteomic strategy reveal combined α1 antitrypsin and cathepsin D as biomarkers for colorectal cancer early screening. J Proteome Res 2010;9:4701-4709.
74.
Besson D, Pavageau AH, Valo I, Bourreau A, Bélanger A, Eymerit-Morin C, Moulière A, Chassevent A, Boisdron-Celle M, Morel A, Solassol J, Campone M, Gamelin E, Barré B, Coqueret O, Guette C: A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker. Mol Cell Proteomics 2011;10:M111.009712.
75.
Kang UB, Yeom J, Kim HJ, Kim H, Lee C: Expression profiling of more than 3,500 proteins of MSS-type colorectal cancer by stable isotope labeling and mass spectrometry. J Proteomics 2012;75:3050-3062.
76.
Wiśniewski JR, Ostasiewicz P, Mann M: High recovery FASP applied to the proteomic analysis of microdissected formalin fixed paraffin embedded cancer tissues retrieves known colon cancer markers. J Proteome Res 2011;10:3040-3049.
77.
Jungblut PR, Zimny-Arndt U, Zeindl-Eberhart E, Stulik J, Koupilova K, Pleissner KP, Otto A, Müller EC, Sokolowska-Köhler W, Grabher G, Stöffler G: Proteomics in human disease: cancer, heart and infectious diseases. Electrophoresis 1999;20:2100-2110.
78.
Røseth AG, Kristinsson J, Fagerhol MK, Schjønsby H, Aadland E, Nygaard K, Roald B: Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993;28:1073-1076.
79.
Roblick UJ, Hirschberg D, Habermann JK, Palmberg C, Becker S, Krüger S, Gustafsson M, Bruch HP, Franzen B, Ried T, Bergmann T, Auer G, Jörnvall H: Sequential proteome alterations during genesis and progression of colon cancer. Cell Mol Life Sci 2004;61:1246-1255.
80.
O'Dwyer D, Ralton LD, O'Shea A, Murray GI: The proteomics of colorectal cancer: identification of a protein signature associated with prognosis. PLoS One 2011;6:e27718.
81.
Gemoll T, Roblick UJ, Szymczak S, Braunschweig T, Becker S, Igl BW, Bruch HP, Ziegler A, Hellman U, Difilippantonio MJ, Ried T, Jörnvall H, Auer G, Habermann JK: HDAC2 and TXNL1 distinguish aneuploid from diploid colorectal cancers. Cell Mol Life Sci 2011;68:3261-3274.
82.
Gemoll T, Habermann JK, Lahmann J, Szymczak S, Lundgren C, Bündgen NK, Jungbluth T, Nordström B, Becker S, Lomnytska MI, Bruch HP, Ziegler A, Hellman U, Auer G, Roblick UJ, Jörnvall H: Protein profiling of genomic instability in endometrial cancer. Cell Mol Life Sci 2012;69:325-333.
83.
Mallow EB, Harris A, Salzman N, Russell JP, DeBerardinis RJ, Ruchelli E, Bevins CL: Human enteric defensins. Gene structure and developmental expression. J Biol Chem 1996;271:4038-4045.
84.
Anderson NL, Anderson NG: The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:845-867.
85.
Martínez-Aguilar J, Chik J, Nicholson J, Semaan C, McKay MJ, Molloy MP: Quantitative mass spectrometry for colorectal cancer proteomics. Proteomics Clin Appl 2013;7:42-54.
86.
Zhang X, Xiao Z, Liu X, Du L, Wang L, Wang S, Zheng N, Zheng G, Li W, Zhang X, Dong Z, Zhuang X, Wang C: The potential role of ORM2 in the development of colorectal cancer. PLoS One 2012;7:e31868.
87.
Ma Y, Peng J, Huang L, Liu W, Zhang P, Qin H: Searching for serum tumor markers for colorectal cancer using a 2-D DIGE approach. Electrophoresis 2009;30:2591-2599.
88.
Ma Y, Zhang P, Wang F, Liu W, Yang J, Qin H: An integrated proteomics and metabolomics approach for defining oncofetal biomarkers in the colorectal cancer. Ann Surg 2012;255:720-730.
89.
Bünger S, Haug U, Kelly FM, Klempt-Giessing K, Cartwright A, Posorski N, Dibbelt L, Fitzgerald SP, Bruch HP, Roblick UJ, von Eggeling F, Brenner H, Habermann JK: Toward standardized high-throughput serum diagnostics: multiplex-protein array identifies IL-8 and VEGF as serum markers for colon cancer. J Biomol Screen 2011;16:1018-1026.
90.
Bünger S, Haug U, Kelly M, Posorski N, Klempt-Giessing K, Cartwright A, Fitzgerald SP, Toner V, McAleer D, Gemoll T, Laubert T, Büning J, Fellermann K, Bruch HP, Roblick UJ, Brenner H, et al: A novel multiplex-protein array for serum diagnostics of colon cancer: a case-control study. BMC Cancer 2012;12:393.
91.
Fernandes LC, Kim SB, Matos D: Cytokeratins and carcinoembryonic antigen in diagnosis, staging and prognosis of colorectal adenocarcinoma. World J Gastroenterol 2005;11:645-648.
92.
Lundberg M, Thorsen SB, Assarsson E, Villablanca A, Tran B, Gee N, Knowles M, Nielsen BS, González Couto E, Martin R, Nilsson O, Fermer C, Schlingemann J, Christensen IJ, Nielsen HJ, Ekström B, et al: Multiplexed homogeneous proximity ligation assays for high-throughput protein biomarker research in serological material. Mol Cell Proteomics 2011;10:M110.004978.
93.
Lundberg M, Eriksson A, Tran B, Assarsson E, Fredriksson S: Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res 2011;39:e102.
94.
Thorsen SB, Lundberg M, Villablanca A, Christensen SL, Belling KC, Nielsen BS, Knowles M, Gee N, Nielsen HJ, Brunner N, Christensen IJ, Fredriksson S, Stenvang J, Assarsson E: Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals. J Transl Med 2013;11:253.
95.
Babel I, Barderas R, Díaz-Uriarte R, Martínez-Torrecuadrada JL, Sánchez-Carbayo M, Casal JI: Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol Cell Proteomics 2009;8:2382-2395.
96.
Barderas R, Babel I, Díaz-Uriarte R, Moreno V, Suarez A, Bonilla F, Villar-Vazquez R, Capella G, Casal JI: An optimized predictor panel for colorectal cancer diagnosis based on the combination of tumor-associated antigens obtained from protein and phage microarrays. J Proteomics 2012;75:4647-4655.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.